Jeffrey S. Parkin

Array ( [id] => 8696965 [patent_doc_number] => 20130058973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'IMMUNE THERAPY' [patent_app_type] => utility [patent_app_number] => 13/636118 [patent_app_country] => US [patent_app_date] => 2011-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 29177 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13636118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8915958 [patent_doc_number] => 20130177583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-11 [patent_title] => 'MOLECULAR CLONE OF HIV-1' [patent_app_type] => utility [patent_app_number] => 13/582319 [patent_app_country] => US [patent_app_date] => 2011-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 12757 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13582319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8683937 [patent_doc_number] => 20130052221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-28 [patent_title] => 'DNA-PROTEIN VACCINATION PROTOCOLS' [patent_app_type] => utility [patent_app_number] => 13/580892 [patent_app_country] => US [patent_app_date] => 2011-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13939 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13580892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8732707 [patent_doc_number] => 20130078276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'VECTORS EXPRESSING HIV ANTIGENS AND GM-CSF AND RELATED METHODS OF GENERATING AN IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 13/579667 [patent_app_country] => US [patent_app_date] => 2011-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 25731 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13579667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8159278 [patent_doc_number] => 20120100632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-26 [patent_title] => 'MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/024093 [patent_app_country] => US [patent_app_date] => 2011-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13849 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0100/20120100632.pdf [firstpage_image] =>[orig_patent_app_number] => 13024093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8335519 [patent_doc_number] => 20120202223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'Ki-67 ASSAY FOR PATIENT IMMUNE SYSTEM STATUS' [patent_app_type] => utility [patent_app_number] => 13/020285 [patent_app_country] => US [patent_app_date] => 2011-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3199 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13020285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102837 [patent_doc_number] => 20110166330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'GPCR crystalization method using an antibody' [patent_app_type] => utility [patent_app_number] => 12/931528 [patent_app_country] => US [patent_app_date] => 2011-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11515 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20110166330.pdf [firstpage_image] =>[orig_patent_app_number] => 12931528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369858 [patent_doc_number] => 20140079731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'Sin Nombre Virus Full-Length M Segment-Based DNA Vaccines' [patent_app_type] => utility [patent_app_number] => 13/982606 [patent_app_country] => US [patent_app_date] => 2011-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23457 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13982606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5935990 [patent_doc_number] => 20110212106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-01 [patent_title] => 'HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/010336 [patent_app_country] => US [patent_app_date] => 2011-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21898 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0212/20110212106.pdf [firstpage_image] =>[orig_patent_app_number] => 13010336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6062289 [patent_doc_number] => 20110200636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-18 [patent_title] => 'METHOD FOR IMPROVING THE BREADTH OF THE IMMUNE RESPONSE TO DIVERSE STRAINS AND CLADES OF HIV' [patent_app_type] => utility [patent_app_number] => 13/010141 [patent_app_country] => US [patent_app_date] => 2011-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 25862 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0200/20110200636.pdf [firstpage_image] =>[orig_patent_app_number] => 13010141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102190 [patent_doc_number] => 20110165683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'CHIMERIC GAMMARETROVIRUS' [patent_app_type] => utility [patent_app_number] => 12/980938 [patent_app_country] => US [patent_app_date] => 2010-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12772 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20110165683.pdf [firstpage_image] =>[orig_patent_app_number] => 12980938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5970419 [patent_doc_number] => 20110151436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION' [patent_app_type] => utility [patent_app_number] => 12/977481 [patent_app_country] => US [patent_app_date] => 2010-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 37000 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0151/20110151436.pdf [firstpage_image] =>[orig_patent_app_number] => 12977481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10084512 [patent_doc_number] => 09121855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-01 [patent_title] => 'Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope' [patent_app_type] => utility [patent_app_number] => 12/977411 [patent_app_country] => US [patent_app_date] => 2010-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 7 [patent_no_of_words] => 37065 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12977411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9468694 [patent_doc_number] => 08722324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => 'Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides' [patent_app_type] => utility [patent_app_number] => 12/977320 [patent_app_country] => US [patent_app_date] => 2010-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 7 [patent_no_of_words] => 37087 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 251 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12977320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8522248 [patent_doc_number] => 20120321655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'LENTIVIRUS VACCINE BASED ON THE RECOMBINANT VIRAL VACCINE AGAINST YELLOW FEVER' [patent_app_type] => utility [patent_app_number] => 13/518876 [patent_app_country] => US [patent_app_date] => 2010-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12189 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13518876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5969118 [patent_doc_number] => 20110150915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'POLYVALENT VACCINE' [patent_app_type] => utility [patent_app_number] => 12/960287 [patent_app_country] => US [patent_app_date] => 2010-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 9582 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12960287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6062151 [patent_doc_number] => 20110200592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-18 [patent_title] => 'Methods For Reducing Viral Load in HIV-1 Infected Patients' [patent_app_type] => utility [patent_app_number] => 12/954464 [patent_app_country] => US [patent_app_date] => 2010-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 31700 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0200/20110200592.pdf [firstpage_image] =>[orig_patent_app_number] => 12954464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6024306 [patent_doc_number] => 20110052632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-03 [patent_title] => 'HIV POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM BOTSWANA MJ4' [patent_app_type] => utility [patent_app_number] => 12/943195 [patent_app_country] => US [patent_app_date] => 2010-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 24750 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0052/20110052632.pdf [firstpage_image] =>[orig_patent_app_number] => 12943195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5943576 [patent_doc_number] => 20110104196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-05 [patent_title] => 'IMMUNOGENIC COMPOSITION AND METHOD OF DEVELOPING A VACCINE BASED ON FUSION PROTEIN' [patent_app_type] => utility [patent_app_number] => 12/940390 [patent_app_country] => US [patent_app_date] => 2010-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19526 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20110104196.pdf [firstpage_image] =>[orig_patent_app_number] => 12940390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465868 [patent_doc_number] => 20120271036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein' [patent_app_type] => utility [patent_app_number] => 13/504690 [patent_app_country] => US [patent_app_date] => 2010-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 28281 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13504690 [rel_patent_id] =>[rel_patent_doc_number] =>)